Secretome Therapeutics Secures $30 Million in Latest Series A Funding Round

Secretome Therapeutics secured $30 million in its latest Series A, adding another data point to the Enterprise Technology funding market.

Secretome Therapeutics Raises $30 million in Funding

Secretome Therapeutics is a Enterprise Technology company focused on Advance STM-01 for Duchenne-Associated Cardiomyopathy.

Investors Behind the Funding

The round was backed by RA Capital Management. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Secretome Therapeutics operates in Enterprise Technology. Secretome Therapeutics's Series A round shows investors are still backing enterprise technology platforms with real scale narratives. At $30M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

Advance STM-01 for Duchenne-Associated Cardiomyopathy

Looking Ahead

Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy

Source reference: original announcement/article.